Abstract
For management of pain, non-steroidal anti-inflammatory drugs (NSAIDs) play a major role. Use of NSAIDs is associated with toxicity, particularly in the gastrointestinal tract and kidney, whereas the use of COX-2 selective NSAIDs is associated with renal failure. Various approaches such as management of COX-1/COX-2 and 5-LOX/COX-2 inhibitors, use of natural products, formulation, drug modification and synthesis of new chemical entities in search of safer anti-inflammatory drugs reported in literature to overcome serious side effects of NSAIDs is summarized in this review. We have also reported recent findings in the area of synthesis of heterocyclic compounds such as pyrimidine, pyridine, thiazole, triazole, imidazole, oxazole, isooxazole, pyrazole , pyrazolidine, pyrole, acridine derivatives and other related heterocyclic compounds and their role as non-selective, COX-2 selective, LOX selective and COX/LOX dual, inhibitors.
Keywords: Heterocyclic compounds, anti-inflammatory agents, non-steroidal
Current Bioactive Compounds
Title: Heterocyclic Compounds as Anti-Inflammatory Agents
Volume: 3 Issue: 2
Author(s): Sham M. Sondhi, Monica Dinodia, Jaiveer Singh and Reshma Rani
Affiliation:
Keywords: Heterocyclic compounds, anti-inflammatory agents, non-steroidal
Abstract: For management of pain, non-steroidal anti-inflammatory drugs (NSAIDs) play a major role. Use of NSAIDs is associated with toxicity, particularly in the gastrointestinal tract and kidney, whereas the use of COX-2 selective NSAIDs is associated with renal failure. Various approaches such as management of COX-1/COX-2 and 5-LOX/COX-2 inhibitors, use of natural products, formulation, drug modification and synthesis of new chemical entities in search of safer anti-inflammatory drugs reported in literature to overcome serious side effects of NSAIDs is summarized in this review. We have also reported recent findings in the area of synthesis of heterocyclic compounds such as pyrimidine, pyridine, thiazole, triazole, imidazole, oxazole, isooxazole, pyrazole , pyrazolidine, pyrole, acridine derivatives and other related heterocyclic compounds and their role as non-selective, COX-2 selective, LOX selective and COX/LOX dual, inhibitors.
Export Options
About this article
Cite this article as:
Sondhi M. Sham, Dinodia Monica, Singh Jaiveer and Rani Reshma, Heterocyclic Compounds as Anti-Inflammatory Agents, Current Bioactive Compounds 2007; 3 (2) . https://dx.doi.org/10.2174/157340707780809554
DOI https://dx.doi.org/10.2174/157340707780809554 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1)
Current Topics in Medicinal Chemistry Lexical Characterisation of Bio-Ontologies by the Inspection of Regularities in Labels
Current Bioinformatics α7-Nicotinic Receptors and Cognition
Current Drug Targets Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design Editorial [Hot Topic: ABC Transporters in Pharmacology/Physiology and Human Diseases (Guest Editor: Zhe-Sheng (Jason) Chen)]
Current Pharmaceutical Biotechnology Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction
Current Pharmaceutical Design Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Anticonvulsant Sulfonamides/Sulfamates/Sulfamides with Carbonic Anhydrase Inhibitory Activity: Drug Design and Mechanism of Action
Current Pharmaceutical Design